

Hindustan Unilever Limited

Recent correction a good entry point

Sector: Consumer Goods
Company Update

	Change
Reco: Buy	↔
CMP: Rs. 2,088	
Price Target: Rs. 2,305	↔

↑ Upgrade ↔ No change ↓ Downgrade


Company details

Market cap:	Rs. 490,569 cr
52-week high/low:	Rs. 2614/1660
NSE volume: (No of shares)	16.6 lakh
BSE code:	500696
NSE code:	HINDUNILVR
Sharekhan code:	HINDUNILVR
Free float: (No of shares)	89.5 cr

Shareholding (%)

Promoters	61.9
FII	12.0
DII	6.3
Others	19.7

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-15.1	-3.3	0.1	23.9
Relative to Sensex	-20.9	19.5	21.6	40.2

Sharekhan Research, Bloomberg

The GSK Group sold a 5.7% stake (13.37 crore shares) in Hindustan Unilever Limited (HUL) through multiple block deals in the open market at an average price of Rs. 1,902 per share. The stock has corrected by ~16% from its high and its currently trading at 48.1x its FY2022E earnings. GSK Group selling the stake has reduced supply overhang on the stock and the current valuations factors in a sluggish Q4 due to supply disruption caused by the nationwide lockdown in the fag-end of the quarter. We expect supply disruption to sustain in the coming months till the time the nation recovers from the pandemic situation. Thus, H1FY2021 would see HUL's sales significantly lower than H1FY2020. However, if the pandemic situation is under control by June/July, we expect recovery in demand to begin from H2FY2020. With half of the portfolio catering to essential categories, the strong direct distribution reach of almost three million retail outlets and new product launches (especially in the hygiene space) would help HUL to see faster recovery post normalisation of business environment. The merger of GSK Consumer Healthcare (GSK Consumer) will make HUL one of the strongest players in domestic processed foods space (~50% of overall FMCG market in India and growing at good pace) and would lead to earnings accretion of 4-8% over FY2021-22.

Innovation remains core of growth strategy; GSK Consumer merger will enhance future earnings growth: Innovation has always remained the core of HUL's growth strategy and will continue to drive growth for the company in the near term. After the lockdown ends, demand for hygiene products is expected to increase. In view of this, HUL has launched products such as Lifebuoy germ skill spray, Domex germ removal wipes and Domex disinfectant spray, etc. Further, recent acquisitions will expand the company's portfolio and will be a key revenue driver in the long run. The penetration level for health food drinks (HFD) in India is just 24% (14% in rural India), which provides a huge scope for HUL in long run. The acquisition of V Wash gives the company an entry into the currently underpenetrated and rapidly growing female intimate hygiene segment, the penetration of which is currently 8-10% in India. This will be well-supported by a strong distribution reach and adequate media spends.

Our Call

Valuation- Retain Buy with price target of Rs. 2,305: HUL is currently operating at 70-80% capacity in most of its manufacturing facilities and focusing on supplying whatever its manufacturing through various distribution models. Though FY2021 is expected to be affected by spread of COVID-19, HUL's long-term growth prospects are intact and we expect a strong recovery in FY2022 (if pandemic situation is under control by H1FY2021). The stock has already corrected by ~16% from its recent high and trading at 48.1x its FY2022E EPS, which is at discount to its last three years average multiple of 55x. Thus, the recent correction provides a good entry opportunity in quality large consumer goods stock such as HUL from a long-term perspective. We maintain our Buy recommendation on the stock with unchanged price target of Rs. 2,305.

Key Risks

If the global pandemic takes time to normalise, it will continue to impact on HUL's earnings in the near term.

Valuation

Particulars	FY18	FY19	FY20	FY21E*	FY22E*
Revenue	35,218	38,224	38,785	41,044	48,323
OPM (%)	20.7	22.6	24.8	25.2	27.0
Adjusted PAT	5,287	6,199	6,886	7,627	10,209
Adjusted EPS (Rs.)	24.5	28.7	31.9	32.5	43.5
P/E (x)	85.3	72.7	65.5	64.3	48.1
P/B (x)	63.7	58.9	56.2	10.3	9.9
EV/EBIDTA (x)	61.1	51.5	46.4	51.4	40.8
RoNW (%)	77.9	84.2	87.8	27.4	21.0
RoCE (%)	104.2	113.2	105.2	35.9	27.9


Source: Company; Sharekhan estimates

* FY2021 and FY2022 earnings estimates include the merger of GSK Consumer

Focus on essentials to help in posting good recovery in H2FY2020

Essential categories (including homecare, personal wash and hygiene products) fetch 50-55% of HUL's overall revenues. HUL has been focusing on manufacturing essential category products in the near term due to high demand, while discretionary categories remain affected amid the pandemic. The management is also focusing on value products and smaller SKUs in premium category products in view of downtrading. Innovative delivery models such as partnering with last-mile delivery apps such as Swiggy and Dunzo will help the company.

Contribution to domestic revenue




Source: Company, Sharekhan Research

GSK Consumer merger will improve the growth prospects in long run: GSK Consumer has a very strong portfolio of brands in the health food drinks (HFD) category. The penetration level for GSK Consumer's brands stands at 24% (14% in rural geographies), which will provide a massive opportunity and lot of synergistic benefits for HUL. The company plans to leverage category leaders, Horlicks and Boost, and focus would be to grow brands with the help of HUL's extensive distribution channels. It is also an opportunity for HUL to drive premiumisation as the premium portfolio of Horlicks is 22%. The merger is in-line with the company's strategy of building a sustainable and profitable foods and refreshment business in India by leveraging the mega-trend of health and wellness. The management is confident of achieving double-digit revenue growth see margins expand by 800-1,000 bps in the medium term. Further the acquisition of V-Wash gives the company an entry into the currently underpenetrated and rapidly growing female intimate hygiene segment, the penetration of which is currently 8-10% in India. The brand has a leadership position and fits well into the white spaces in the beauty and personal care business.


Financials in charts

Volumes declined by 7% in Q4FY2020




Source: Company, Sharekhan Research

GPM improved y-o-y in Q4, OPM saw slight dip




Source: Company, Sharekhan Research

Revenue & PAT CAGR of 3.7% & 13.4% over FY16-20




Source: Company, Sharekhan Research

Key categories impacted by lockdown




Source: Company, Sharekhan Research

Working Capital remained negative



Source: Company, Sharekhan Research

Strong dividend payout maintained



Source: Company, Sharekhan Research


Outlook

Recovery expected post normalisation of the pandemic situation: Q4FY2020 performance was affected by disruption in supply chain at the fag-end of the quarter due to a nationwide lockdown. With the lockdown continuing in April-May, supply disruption is expected to continue though production of essential products has scaled up to 70-80% in many facilities. Thus, Q1FY2021 is expected to be another disappointing quarter with significant loss in revenue and profitability. If the pandemic situation gets under control by June-July, we expect sales to normalise from Q3FY2021 (largely in essential categories). Discretionary categories (such as skin care and hair care) will take some time to regain momentum. We expect performance to fully recover in FY2022. On the other hand, stringent cost-cutting measures and reduction of advertisement spends would provide some support to OPM in the near term.

Valuation

Retain Buy with price target of Rs. 2,305: HUL is currently operating at 70-80% capacity in most of its manufacturing facilities and focusing on supplying whatever its manufacturing through various distribution models. Though FY2021 is expected to be affected by spread of COVID-19, HUL's long-term growth prospects are intact and we expect a strong recovery in FY2022 (if pandemic situation is under control by H1FY2021). The stock has already corrected by ~16% from its recent high and trading at 48.1x its FY2022E EPS, which is at discount to its last three years average multiple of 55x. Thus, the recent correction provides a good entry opportunity in quality large consumer goods stock such as HUL from a long-term perspective. We maintain our Buy recommendation on the stock with unchanged price target of Rs. 2,305.

One year forward P/E (x) band



Source: Sharekhan Research

Peer Comparison

Particulars	P/E (x)			EV/EBIDTA (x)			RoCE (%)		
	FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E
Nestle India*	87.1	76.9	62.9	59.5	53.7	44.8	96.9	138.2	126.2
ITC	13.2	12.6	11.2	9.0	8.5	7.5	27.5	28.1	30.7
HUL	65.5	64.3	48.1	46.4	51.4	40.8	105.2	35.9	27.9

Source: Company, Sharekhan estimates

*Values for Nestle India are for CY2019, CY2020E and CY2021E

About company

HUL is India's largest FMCG company with a strong presence in the homecare and beauty and personal care categories. The company is a subsidiary of Unilever Plc (that holds a 67% stake in HUL), the world's largest consumer goods company present across 190 countries. With over 40 brands spanning 12 distinct categories such as personal wash, fabric wash, skin care, hair care, oral care, deodorants, colour cosmetics, beverages, ice creams, frozen desserts and water purifiers, HUL is part of the everyday life of millions of consumers across India. The company's portfolio includes leading brands such as Lux, Lifebuoy, Surf Excel, Rin, Wheel, Fair & Lovely, Pond's, Vaseline, Lakmé, Dove, Clinic Plus, Sunsilk and Axe. HUL reported revenue of Rs. 38,224 crore and OPM of 22.6% in FY2019.

Investment theme

HUL has a leadership position in highly penetrated categories such as soaps, detergents and shampoos in India. Sustaining product innovation, entering into new categories, premiumisation and increased distribution network remain some of the key revenue drivers for the company. The recent acquisition of GSK Consumer will make HUL a formidable play in the HFD segment and will enhance the growth prospects of its relatively small food business. A strong financial background, robust cash generation ability and leadership position in some key categories give HUL an edge over other companies and, hence, justify the stock's premium valuation.

Key Risks

- ◆ **Slowdown in the demand environment:** Any slowdown in demand (especially in rural India) would affect sales of key categories, resulting in moderation of sales volume growth.
- ◆ **Increased input prices:** Palm oil and crude derivatives such as linear alkyl benzene are some of the key raw materials used by HUL. Any significant increase in the prices of some of these raw materials would affect profitability and earnings growth.
- ◆ **Increased competition in highly penetrated categories:** Increased competition in highly penetrated categories such as soaps and detergents would act as a threat to revenue growth.

Additional Data

Key management personnel

Sanjiv Mehta	Chairman and Managing Director
Srinivas Pathak	Executive Director, Finance & IT and CFO
Pradeep Bannerjee	Executive Director, Supply Chain
Dev Bajpai	Executive Director, Legal and Corporate Affairs and Company Secretary

Source: Company

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Vanguard Group Inc	1.2
2	BlackRock Inc	1.1
3	Nomura Holdings Inc	0.7
4	SBI Funds Management Pvt Ltd	0.7
5	ICICI Prudential Life Insurance Co Ltd	0.4
6	Standard Life Aberdeen PLC	0.4
7	ICICI Prudential Asset Management Co Ltd	0.3
8	J P Morgan Chase & Co	0.3
9	UTI Asset Management Co Ltd	0.3
10	Government Pension Investment Fund	0.2

Source: Bloomberg,

*Shareholding as on 17th March, 2020

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.